Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations
RKI edoc (Robert Koch-Institut) · 30.04.2021 · 9 · Doc02-Doc02
DOI: 10.3205/id000071 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RKI edoc (Robert Koch-Institut), erschienen am 30.04.2021. Verfasst von Susanne C Duwe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Robert Koch Institute, Unit 17: Influenza and Other Respiratory Viruses, National Reference Centre for Influenza, Berlin, Germany. Die Arbeit wurde bisher 28-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Influenza viruses of types A and B attack 5–10% of adults and 20–30% of children, thereby causing millions of acute respiratory infections in Germany annually. A significant number of these infections are associated with complications such as pneumonia and bacterial superinfections that need hospitalization and might lead to death. In addition to vaccines, drugs were developed that might support influenza prevention and that can be used to treat influenza patients. The timely application of anti-influenza drugs can inhibit virus replication, help reduce and shorten the symptoms, and prevent death as well as virus transmission. This review concisely describes the mechanism of action, the potential for prophylactic and therapeutic use, and the knowledge on resistance of anti-influenza drugs approved today. However, the main aim is to give an overview on the recommendations available in Germany for the proper use of these drugs. In doing so, the recommendations published in statements and guidelines of medical societies as well as the German influenza pandemic preparedness plan are summarized with the consideration of specific circumstances and groups of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Robert Koch Institute, Unit 17: Influenza and Other Respiratory Viruses, National Reference Centre for Influenza, Berlin, Germany.
- Institute for Clinical Microbiology and Hygiene, Regensburg University Hospital, Regensburg, Germany.
- Institute of Medical Microbiology & Hygiene, Saarland University Medical Center, Homburg, Germany.
- Institute for Virology, University Hospital Düsseldorf, Faculty of Medicine, University Düsseldorf, Germany.
- Institute for Infection Medicine, University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
- Section Experimental Virology, Department of Medical Microbiology, Jena University Hospital, Germany.
Zitieren
APA
Duwe, S. C., Schmidt, B., Gärtner, B. C., Timm, J., Adams, O., Fickenscher, H., & Schmidtke, M. (2021). Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. RKI edoc (Robert Koch-Institut), 9, Doc02-Doc02. https://doi.org/10.3205/id000071
Vancouver
Duwe SC, Schmidt B, Gärtner BC, Timm J, Adams O, Fickenscher H, et al. Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. RKI edoc (Robert Koch-Institut). 2021;9:Doc02-Doc02. doi:10.3205/id000071
BibTeX
@article{Duwe2021,
author = {Duwe, Susanne C and Schmidt, Barbara and Gärtner, Barbara C and Timm, Jörg and Adams, Ortwin and Fickenscher, Helmut and Schmidtke, Michaela},
title = {Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations},
journal = {RKI edoc (Robert Koch-Institut)},
year = {2021},
volume = {9},
pages = {Doc02--Doc02},
doi = {10.3205/id000071}
}
EUVIMED